Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project

Eline A. J. Willemse, Ingrid S. van Maurik, Betty M. Tijms, Femke H. Bouwman, Andreas Franke, Isabelle Hubeek, Leo Boelaarts, Jules J. Claus, Esther S. C. Korf, Rob J. van Marum, Gerwin Roks, Niki Schoonenboom, Nicolaas Verwey, Marissa D. Zwan, Simone Wahl, Wiesje M. van der Flier, Charlotte E. Teunissen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction: We compared the automated Elecsys and manual Innotest immunoassays for cerebrospinal fluid (CSF) Alzheimer's disease biomarkers in a multicenter diagnostic setting. Methods: We collected CSF samples from 137 participants in eight local memory clinics. Amyloid β(1–42) (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) were centrally analyzed with Innotest and Elecsys assays. Concordances between methods were assessed. Results: Biomarker results strongly correlated between assays with Spearman's ρ 0.94 for Aβ42, 0.98 for t-tau, and 0.98 for p-tau. Using Gaussian mixture modeling, cohort-specific cut-points were estimated at 1092 pg/mL for Aβ42, 235 pg/mL for t-tau, and 24 pg/mL for p-tau. We found an excellent concordance of biomarker abnormality between assays of 97% for Aβ42 and 96% for both t-tau and p-tau. Discussion: The high concordances between Elecsys and Innotest in this nonacademic, multicenter cohort support the use of Elecsys for CSF Alzheimer's disease diagnostics and allow conversion of results between methods.
Original languageEnglish
Pages (from-to)563-572
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume10
DOIs
Publication statusPublished - 2018

Cite this

@article{21cf1815d5134f57840f085e8e9ba020,
title = "Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project",
abstract = "Introduction: We compared the automated Elecsys and manual Innotest immunoassays for cerebrospinal fluid (CSF) Alzheimer's disease biomarkers in a multicenter diagnostic setting. Methods: We collected CSF samples from 137 participants in eight local memory clinics. Amyloid β(1–42) (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) were centrally analyzed with Innotest and Elecsys assays. Concordances between methods were assessed. Results: Biomarker results strongly correlated between assays with Spearman's ρ 0.94 for Aβ42, 0.98 for t-tau, and 0.98 for p-tau. Using Gaussian mixture modeling, cohort-specific cut-points were estimated at 1092 pg/mL for Aβ42, 235 pg/mL for t-tau, and 24 pg/mL for p-tau. We found an excellent concordance of biomarker abnormality between assays of 97{\%} for Aβ42 and 96{\%} for both t-tau and p-tau. Discussion: The high concordances between Elecsys and Innotest in this nonacademic, multicenter cohort support the use of Elecsys for CSF Alzheimer's disease diagnostics and allow conversion of results between methods.",
author = "Willemse, {Eline A. J.} and {van Maurik}, {Ingrid S.} and Tijms, {Betty M.} and Bouwman, {Femke H.} and Andreas Franke and Isabelle Hubeek and Leo Boelaarts and Claus, {Jules J.} and Korf, {Esther S. C.} and {van Marum}, {Rob J.} and Gerwin Roks and Niki Schoonenboom and Nicolaas Verwey and Zwan, {Marissa D.} and Simone Wahl and {van der Flier}, {Wiesje M.} and Teunissen, {Charlotte E.}",
year = "2018",
doi = "10.1016/j.dadm.2018.08.006",
language = "English",
volume = "10",
pages = "563--572",
journal = "Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project

AU - Willemse, Eline A. J.

AU - van Maurik, Ingrid S.

AU - Tijms, Betty M.

AU - Bouwman, Femke H.

AU - Franke, Andreas

AU - Hubeek, Isabelle

AU - Boelaarts, Leo

AU - Claus, Jules J.

AU - Korf, Esther S. C.

AU - van Marum, Rob J.

AU - Roks, Gerwin

AU - Schoonenboom, Niki

AU - Verwey, Nicolaas

AU - Zwan, Marissa D.

AU - Wahl, Simone

AU - van der Flier, Wiesje M.

AU - Teunissen, Charlotte E.

PY - 2018

Y1 - 2018

N2 - Introduction: We compared the automated Elecsys and manual Innotest immunoassays for cerebrospinal fluid (CSF) Alzheimer's disease biomarkers in a multicenter diagnostic setting. Methods: We collected CSF samples from 137 participants in eight local memory clinics. Amyloid β(1–42) (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) were centrally analyzed with Innotest and Elecsys assays. Concordances between methods were assessed. Results: Biomarker results strongly correlated between assays with Spearman's ρ 0.94 for Aβ42, 0.98 for t-tau, and 0.98 for p-tau. Using Gaussian mixture modeling, cohort-specific cut-points were estimated at 1092 pg/mL for Aβ42, 235 pg/mL for t-tau, and 24 pg/mL for p-tau. We found an excellent concordance of biomarker abnormality between assays of 97% for Aβ42 and 96% for both t-tau and p-tau. Discussion: The high concordances between Elecsys and Innotest in this nonacademic, multicenter cohort support the use of Elecsys for CSF Alzheimer's disease diagnostics and allow conversion of results between methods.

AB - Introduction: We compared the automated Elecsys and manual Innotest immunoassays for cerebrospinal fluid (CSF) Alzheimer's disease biomarkers in a multicenter diagnostic setting. Methods: We collected CSF samples from 137 participants in eight local memory clinics. Amyloid β(1–42) (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) were centrally analyzed with Innotest and Elecsys assays. Concordances between methods were assessed. Results: Biomarker results strongly correlated between assays with Spearman's ρ 0.94 for Aβ42, 0.98 for t-tau, and 0.98 for p-tau. Using Gaussian mixture modeling, cohort-specific cut-points were estimated at 1092 pg/mL for Aβ42, 235 pg/mL for t-tau, and 24 pg/mL for p-tau. We found an excellent concordance of biomarker abnormality between assays of 97% for Aβ42 and 96% for both t-tau and p-tau. Discussion: The high concordances between Elecsys and Innotest in this nonacademic, multicenter cohort support the use of Elecsys for CSF Alzheimer's disease diagnostics and allow conversion of results between methods.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85055470742&origin=inward

U2 - 10.1016/j.dadm.2018.08.006

DO - 10.1016/j.dadm.2018.08.006

M3 - Article

VL - 10

SP - 563

EP - 572

JO - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

JF - Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

SN - 2352-8729

ER -